食品药品监督管理局
医学
医学物理学
药方
药品
药品审批
临床研究
临床疗效
包装说明书
临床试验
重症监护医学
药理学
病理
内科学
作者
Alex Gorovets,Louis Marzella,Dwaine Rieves,Lucie L. Yang
标识
DOI:10.2967/jnumed.112.117804
摘要
The safety and efficacy expectations for U.S. Food and Drug Administration (FDA) approval of diagnostic radiopharmaceuticals (DRs) are described in laws that broadly apply to all prescription drugs and biologic products. These laws also outline efficacy expectations that are unique for DRs. The FDA regulations and guidance documents elaborate on DR efficacy expectations for clinical uses of the drugs, such as the delineation of anatomy, the characterization of a physiologic process, or the diagnosis of disease. As described in the FDA regulations, the approval of a DR necessitates that the imaging drug has the ability to provide clinically useful information. Here we cite approved DRs to illustrate how the imaging performance of the drugs was characterized in clinical studies and the clinical usefulness of the imaging information described in drug labels.
科研通智能强力驱动
Strongly Powered by AbleSci AI